

NOW RECRUITING:

IMMUNOLIGHT THERAPY FOR CANINE CANCER



With the support of the Immunolight team, doctors in the department of Radiation Oncology at NC State's College of Veterinary medicine are working with researchers at Duke University's School of Medicine to develop Immunolight therapy. This innovative therapy offers a promising new approach to treating cancer in dogs.

The goal of this study is to evaluate the safety of Immunolight therapy in canine cancer patients. Information gathered in this study will be used to tell us more about how this therapy can be effectively used for treatment of various solid malignancies in dogs and people.

Eligibility:

- Peripheral malignancies (2-6 cm) accessible for repeated intratumoral injection
- Otherwise healthy dogs, free of metastasis
- May not receive other treatments for their tumor prior to or during enrollment in study
- Predicted survival > 3 months without cancer treatment and no concurrent illness associated with a clinical prognosis for survival < 1 year
- No disease necessitating the use of chronic anti-inflammatory or immunosuppressive drug therapy, or history of autoimmune disease

Tumor examples include:

- *Soft tissue sarcoma (e.g., spindle cell tumors, fibrosarcoma, hemangiopericytoma, nerve sheath tumor, liposarcomas, etc.)*
- *Perianal tumors (adenomas and carcinomas)*
- *Anal sac tumors*
- *Digital tumors (e.g., squamous cell carcinomas and melanomas)*
- *Skin tumors (melanoma, squamous cell carcinoma, basal cell carcinoma, sebaceous gland tumors, round cell tumors, TVT, trichoblastoma, trichoepithelioma, etc.)*
- *Rostral oral tumors*

This study is financially supported by the Immunolight Company and NC State

Study benefits include:

- Free staging tests
- Free Immunolight therapy sessions
- Free recheck examinations

A total value of ~\$4570, without the support of this clinical trial!

Additional benefits:

- *A study completion incentive of \$1250*
- *A contribution of up to \$1000 for treatment of unexpected complications directly associated with Immunolight therapy.*

Care for side effects must be provided at NC State, under the guidance of a radiation oncologist

For more information contact: [Clinical Studies Core](#)

Phone: 919-515-2633 or 919-513-6384; Fax: 919-513-6680, Email: ccmtr_csc@ncsu.edu

Would you like to explore how you can partner with the Clinical Studies Core and support discoveries that save lives? Email janettif@ncsu.edu or the North Carolina Veterinary Medical Foundation, Inc. for more information.